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Introduction
The endothelin system is a potent endothelial system that
controls vascular tone and regulates regional blood flow [1].
Today, three isoforms of the endothelin peptide have been
described (endothelin-1, -2 and -3) but most biological effects
of endothelin are mediated by the 21 amino acid endothelin-1.
In addition to its vascular properties, endothelin influences cell
proliferationand extracellularmatrix synthesis and contributes
to the homeostasis of water and electrolytes by direct effects
on the kidney [1]. Endothelin acts through the activation of
two specific G-protein-coupled receptors, i.e. endothelin Type
A (ETA) and endothelin Type B (ETB) receptors. Stimulation
of vascular ETA receptors induces vasoconstriction, whereas
activation of vascular ETB receptors promotes vasodilatation.
Therefore, the impact of endothelin on vascular tone will
depend on the balance between the ETA and ETB receptor
activation. Since its discovery, the endothelin system has been
implicated in the pathophysiology of several diseases includ-
ing essential arterial hypertension, pulmonary hypertension,
congestive heart failure, acute kidney injury and more recently
the progression of chronic kidney diseases (CKDs) [2–5].
Since 1992, several peptidic and non-peptidic endothelin
receptor antagonists have been synthesized (Table 1) [6]. An-
imal studies using these antagonists have provided promising
results in different indications but today, except for the man-
agement of pulmonary hypertension, the clinical development
of endothelin receptor antagonists has been relatively slow
and their use for the management of essential arterial hyper-
tension is still under investigation. The purpose of this review
is to discuss the potential role of endothelin receptor antago-
nists in the management of arterial essential hypertension and
perhaps in the prevention of the progression of CKDs.
Endothelin receptor blockade in hypertension
Because of its important vascular properties, the endothelin
system has naturally been considered as a potential mech-
anism in the development and maintenance of arterial
hypertension. The infusion of exogenous endothelin has
indeed been shown to raise blood pressure significantly
in animals as well as in humans [7]. The possibility that
endothelin generates arterial hypertension was further con-
sidered with the observation that two patients suffering
from a malignant form of hemangioendothelioma, a vascu-
lar tumour-secreting endothelin, presented with marked
hypertension [8]. High plasma endothelin concentrations
have been measured in malignant hypertension and preg-
nancy-induced hypertension and also in Afro-Americans
[7–10]. At last, a greater vasoconstrictor effect of exoge-
nous endothelin has been found in hypertensive patients
when compared to healthy subjects [9].
In animal models, endothelin receptor antagonists are
effective in lowering blood pressure in salt-sensitive hyper-
tensive models and in stroke prone and malignant hyper-
tension models [11]. In contrast, endothelin receptor
blockade appears to be ineffective in renin-dependent mod-
els of hypertension. In addition to lowering blood pressure,
endothelin antagonists have been shown to have favourable
effects on cardiovascular remodelling, on the incidence of
stroke and on the progression of renal lesions in animals
[11, 12].
In healthy normotensive subjects, the administration of a
non-selective endothelin antagonist decreases peripheral
arterial resistances leading to a decrease in blood pressure
[13]. However, the infusion of a selective ETB antagonist
increases vascular resistances suggesting that the hypoten-
sive effect of non-selective antagonists is due essentially to
the blockade of ETA receptors [14].
The first large study in essential arterial hypertension
compared the anti-hypertensive efficacy of increasing
doses of the non-selective endothelin antagonist bosentan
with that of enalapril 20 mg and a placebo [15]. The study
was conducted in patients with Stage 1–2 hypertension. In
this study, bosentan effectively lowered blood pressure and
endothelin receptor blockade was significantly superior to
placebo but comparable to enalapril. Interestingly, there
was no clear dose–response for the anti-hypertensive effect
of bosentan between 500 and 2000 mg. The incidence of
side effects essentially headaches, flushes and leg oedema
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was significantly higher in the bosentan than in the placebo
group. For these reasons, the concept of endothelin receptor
blockade in essential hypertension was put aside for a
while. Additional studies in essential hypertension have
been conducted using darusentan and atrasentan, two
ETA selective antagonists. Both ETA receptor antagonists
were superior to placebo but these agents were not com-
pared to any recognized anti-hypertensive therapy [16, 17]
(Table 2).
More recently, new studies have been conducted in pa-
tients with resistant hypertension, i.e. patients with uncon-
trolled blood pressure despite a triple therapy including a
diuretic [18–20]. As there is an important medical need for
these high cardiovascular risk patients, endothelin
antagonists have been considered an interesting new ther-
apeutic approach in this indication. Indeed, because these
patients have a high incidence of cardiovascular complica-
tions, the tolerability profile of endothelin antagonists
remains favourable when compared with the global risk
of target organ damages.
In the DORADO program, the first study demonstrated
that the addition of darusentan to a triple therapy was supe-
rior to the addition of a placebo [19]. This study included
patients with an impaired renal function and proteinuria
and the addition of darusentan was also associated with a
reduction in urinary protein excretion. Unfortunately, the
early favourable results of darusentan in resistant hyper-
tension were not confirmed in the latest study [20]. In this
randomized controlled trial, a major placebo effect was
observed at Week 14, whereas at Week 8, there was a
significant difference between the blood pressure lowering
effect of darusentan versus placebo or the alpha blocker,
guanfacine. These disturbing results were probably due to
technical problems linked to the measurement of office
blood pressure. Indeed, when blood pressure was assessed
using ambulatory monitoring, which avoids the placebo
effect, a marked and significant effect of darusentan was
observed [20]. Thus, it seems that ETA receptor blockade
can provide clinical benefits in patients with resistant hy-
pertension but these data should be confirmed with addi-
tional well-conducted randomized trials. In terms of
tolerability profile, the major side effect of darusentan
was again fluid retention with a decrease in haematocrit
due to haemodilution [18–20].
Endothelin receptor antagonists: a potential role
in renal protection?
Endothelin-1 also exerts opposing effects on the kidney
associated with the activation of vascular and tubular endo-
thelin receptors [21, 22]. Through renal vascular ETA recep-
tors, endothelin-1 induces a vasoconstriction of renal
afferent and efferent arterioles. Thus, infusion of endothe-
lin-1 decreases renal blood flow and glomerular filtration
rate and eventually reduces urine flow rate and urinary
sodium excretion. A contrario activation of tubular ETB
receptors increases urine output and sodium excretion. Thus,
blockade of ETA, in contrast to ETB receptor blockade, has
been recognized as a potential mean to lower filtration frac-
tion and hence proteinuria. This property of selective ETA
receptor blockers was nicely demonstrated in animals and in
a small set of patients with CKDs [12, 23–25]. Interestingly,
the impact of ETA receptor blockade was more prominent in
CKD patients than in healthy subjects suggesting that the
contribution of the endothelin system to the regulation of
renal haemodynamics is important mainly in patients with
renal diseases [22].
In CKD patients, several small studies using different
agents have demonstrated that endothelin receptor block-
ers, essentially ETA receptor blockers, lower blood
pressure and/or proteinuria [23, 24, 26–29]. Of note, the
anti-proteinuric effect of ETA blockade was observed even
in patients already treated with a blocker of the renin–
angiotensin system, suggesting an additive effect [30,
31]. In one study, the effect of the endothelin antagonist
sitaxsentan on proteinuria was superior to that of a placebo
or nidefipine, despite comparable decreases in blood pres-
sure when compared with nifedipine 10 mg [32].
The ability of ETA receptor blockade to lower proteinu-
ria urged investigators to perform a large Phase III study in
patients with diabetic nephropathy and proteinuria already
on a blocker of the renin–angiotensin system [33]. In this
randomized controlled trial, two doses of avosentan (25
and 50 mg) were compared to placebo and the main objec-
tives of the study were the changes in proteinuria and
the progression of the diabetic nephropathy. At 6 months,
a significant decrease in albumin/creatinine ratio was
obtained with both doses of avosentan but not with the
placebo. Unfortunately, the impact on the progression of
diabetic nephropathy could not be investigated because the
study was interrupted prematurely. Indeed, the safety com-
mittee reported an increased incidence of fluid overload
leading to heart failure in patients receiving the two doses
of avosentan [33]. This finding therefore corroborated the
observations made previously with other endothelin antag-
onists as discussed above.
In order to clarify the mechanisms leading to the devel-
opment of fluid overload with endothelin receptor antago-
nist, a mechanistic study was designed to investigate the
dose-dependent renal effects of avosentan in healthy subjects
[34]. The results of this placebo-controlled study demonstra-
ted that avosentan indeed induces fluid and sodium retention
at high doses (>10 mg/day) in healthy subjects. The fluid
retention leads to a significant weight gain and decrease in
haematocrit after 1 week of administration. At lower doses
Table 1. Non-peptide endothelin receptor antagonists and their relative
selectivity for endothelin receptorsa
Drug name Chemical class
Relative selectivity
ETA/ETB
Bosentan Pyrimidine sulfonamide 20
Tezosentan Pyrimidine sulfonamide 30
Avosentan Pyrimidine sulfonamide 50–600
Enrasentan Carboxylic acid 110
Darusentan Propanoic acid 130–170
Ambrisentan Propanoic acid 200
Clazosentan Pyrimidine sulfonamide 1000–3200
Atrasentan Carboxylic acid 1860
Sitaxsentan Heteroarylsufonamide 7000
Edonentan Biphenylsulfonamide 80 000
aAdapted from reference [6].
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(1.5 and 5 mg), this effect was not observed suggesting that
it might be linked to the loss of receptor selectivity when
high doses of the ETA antagonist are administered. Of note,
a decrease in haematocrit upon administration of high doses
of avosentan has also been found in anephric rats indicating
that other mechanisms than sodium and water retention
by the kidney may play a role [35]. We have hypothesized
that a drug-induced extravasation of fluid as observed with
potent peripheral vasodilators may also contribute to the
development of oedema in subjects receiving endothelin
antagonists.
Taken together, these data confirm that endothelin recep-
tor blockade can lower proteinuria but the benefits of these
drugs may be limited by their tolerability profile. Thus,
additional studies with well dosed and highly selective
ETA antagonists should be conducted in the future to in-
vestigate the real potential of this therapeutic approach for
renal protection.
Conclusions
There is increasing evidence that endothelin receptor antag-
onists have some clinical potential in the management of
essential hypertension and probably also to retard the pro-
gression of renal diseases. However, at this stage, several
issues need to be resolved before this approach can be
considered for our patients. Firstly, it is obvious that
highly selective ETA receptor antagonists should be de-
veloped rather than poorly selective blockers. Indeed, the
impact on blood pressure and proteinuria appears to be
mediated essentially by ETA receptor blockade. In this
respect, it is of major importance to define as precisely as
possible the dose–response curve of any new agent in
order to avoid a lack of selectivity and thereby increase
the side effect profile. Secondly, the development of en-
dothelin receptor antagonists further emphasizes the im-
portance of understanding the mechanisms of the major
side effects. Thus, the exact role of ETB receptors in the
occurrence of fluid overload needs to be clarified and the
precise mechanisms of fluid retention should be investi-
gated further in susceptible patients. Indeed, in the AS-
CEND trial, it appears that fluid retention was very
sensitive to loop diuretics and rapidly reversible. Com-
bining an endothelin antagonist with a diuretic might
perhaps be one way to limit the incidence of fluid over-
load if renal mechanisms are predominant. In any case, it
seems too early to abandon the development of endothe-
lin receptor antagonists for the management of cardiovas-
cular and renal diseases as we may miss therapeutic
opportunities.
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